Similar results were also found in additional TGF-β-rich models of LLC1 (Supplementary Fig. 7A, B), ID8 (Supplementary Fig. 7C, D), and MC38-HS (Supplementary Fig. 7E, F), in which anti-4-1BB treatment was insufficient (LLC1) or unable (ID8 and MC38-HS) to alter the frequency of CD73+ subset in tumor-infiltrating CD8+ T cells, and combination of anti-CD73/anti-4-1BB failed to induce the synergistic/additive anti-tumor effect. Here, CD8A is linked to neoplasm.